Premium
P4‐010: OBSERVATIONS ON COACHING IN MANAGING LIFESTYLE AND BEHAVIORAL CHANGES IN PERSONALIZED MULTIMODAL CARE PLANS FOR COGNITIVE IMPAIRMENT
Author(s) -
Robbins Tammy,
Gorniak Mary C.,
Lindgren Marianne,
Walker John Q.,
Sabbagh Marwan N.
Publication year - 2018
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2018.06.2412
Subject(s) - coaching , health coaching , cognition , medicine , population , health care , dementia , cognitive decline , terminology , gerontology , psychology , psychiatry , linguistics , philosophy , environmental health , disease , pathology , economics , psychotherapist , economic growth
and PD effects of 500 mg and 1000 mg OAA doses on AD participants. Methods:We obtained FDG PET scans on AD participants prior to starting a one month 500 mg twice daily (n1⁄414) or 1000 mg twice daily (n1⁄47) treatment intervention. We also obtained post-intervention FDG PET scans. We quantified the FDG PET signal from 7 different regions of interest (ROIs), and compared regional pre and post-intervention values. Results: In 6 of the 7 FDG PET ROIs, relative to the 500 mg twice daily group the 1000 mg twice daily group trended towards a favorable response (either increased FDG PET signal at 1 month, or less decline at 1 month). Participants in the 1000mg twice daily group showed a significant 2.5% increase in their hippocampal signal (p<0.05, paired T-test, nominal). The mean change in the 1000 mg twice daily group (2.5% mean increase, 0.9% standard error) also exceeded the mean change of the 500 mg twice daily group (0.3% mean decline, 0.7% standard error) (p<0.05, unpaired T-test). Conclusions: This TOAD study interim analysis suggests OAA at 1000 mg twice daily may engage brain bioenergetic metabolism. Whether or not positive findings persist at the conclusion of this study remains to be seen.